Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19796211 | 0.83 | KDM4C (0.40) | KDM4CNPC1RAB9AL3MBTL1P2RX3 | |
| SCHEMBL248797 | 0.78 | KDM4C (0.36) | KDM4CNPC1RAB9AL3MBTL1AAK1 | |
| SCHEMBL13642329 | 0.76 | MEN1 (0.40) | KDM4CNPC1RAB9AL3MBTL1AAK1 | |
| SCHEMBL578792 | 0.75 | MEN1 (0.50) | KDM4CNPC1RAB9AL3MBTL1AAK1 | |
| SCHEMBL19796213 | 0.74 | NPC1 (0.39) | KDM4CNPC1RAB9AL3MBTL1P2RX3 | |
| SCHEMBL2146505 | 0.73 | MEN1 (0.39) | KDM4CNPC1RAB9AL3MBTL1AAK1 | |
| SCHEMBL19796217 | 0.73 | NPC1 (0.36) | KDM4CNPC1RAB9AL3MBTL1P2RX3 | |
| SCHEMBL30776632 | 0.72 | LPL (0.53) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL15904080 | 0.71 | MEN1 (0.56) | KDM4CNPC1RAB9AL3MBTL1AAK1 | |
| SCHEMBL21912263 | 0.71 | DGAT1 (0.46) | KDM4CNPC1RAB9AL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | KDM4C 1472/4885NPC1 1287/4885RAB9A 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.